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Abstract
Purpose Intravitreal anti-vascular endothelial growth factor
(VEGF) agents are effective in the treatment of central involv-
ing diabetic macular oedema (DMO). Vitreoretinal interface
abnormalities (VRIA) are common in patients with DMO, and
the effect of these on the response to anti-VEGF treatment is
unclear. Furthermore the effect of anti-VEGF agents on the
VRIA itself is uncertain.
Method Prospective study of consecutive patients treated with
ranibizumab (RZB) for DMO as part of routine clinical care in
one eye unit over a 1-year period. Visual acuity (Va), central
retinal thickness (CRT) and injection frequency data was re-
corded on an electronic database. Treatment was initiated with
four monthly RZB injections and then a monthly PRN regime.
All patients underwent high-density spectral-domain optical
coherence tomography (SDOCT) at baseline and 12 months.
The SDOCTs were graded by two observers masked to the
outcome.
Results One hundred and four eyes (77 patients) were includ-
ed in the analysis. The mean age was 62 years, and 62% were
male. The mean presenting vision was 62 letters and CRT
472 μm. Eighty eyes retained stable Va, and 17 had an im-
provement in Va. At baseline, 39 eyes had associated focal
vitreomacular adhesion (VMA) and by 12 months this re-
duced to 30 (p = 0.04), with 12 releasing VMA and three
developing it. Patients with VMA had significantly better final
Va than those without VMA. Improvement in CRT was
greatest in those where VMA released during the study.
Forty-five eyes had some degree of foveal involving epiretinal
membrane (ERM) at baseline, and 28 were considered to have
clinically significant ERM. There was no clinically relevant
change in ERM during the study. Patients with significant
ERM at baseline had a lower final vision. Multivariate analy-
sis showed that ERM and more severe retinopathy at baseline
were predictive of less visual improvement (p < 0.01). Shorter
intraretinal cyst length, ERM and the absence of VMA at
baseline were predictive of a worsened anatomical response
(p < 0.001).
Conclusion VRIA are related to outcome in patients treated
with RZB. ERM was associated with a worsened visual and
anatomic response, and VMA with an improved anatomical
response particularly when spontaneous VMA release oc-
curred during treatment. The presence and severity of ERM
was not affected by RZB treatment.
Keywords Anti VEGF . Ranibizumab . Epiretinal
membrane . Vitreomacular adhesion . Diabetic macular
oedema . Vitreoretinal interface abnormality . Real-world
outcomes
Introduction
It is well known that there is a high prevalence of vitreoretinal
interface abnormalities (VRIA) in patients with diabetic
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macular oedema (DMO [1–6]. Epiretinal membrane (ERM)
and incomplete vitreoretinal separation with vitreomacular at-
tachment (VMA) and traction (VMT) have been described
and related to pathological changes in the vitreous and
vitreoretinal interface [7–9]. As well as the association of
VRIA with DMO, a causative role has also been postulated
and surgical relief of traction demonstrated to be of benefit in
some patients [10–12].
Anti-VEGF agents have been shown to improve clinical
outcomes in patients with centre involving DMO compared
to laser [13]. The presence, however, of VRIA on the response
to anti-VEGF agents in patients with DMO has had limited
study, although there is some data to suggest that they reduce
the therapeutic effect [14]. These agents have also been shown
to alter the balance between angiogenic and fibrotic growth
factors in patients with diabetic retinopathy, termed the
angiofibrotic switch which can result in increased retinal trac-
tion in some patients with proliferative diabetic retinopathy
(PDR) prior to surgery [15].
We carried out a prospective study on a consecutive cohort
of patients undergoing treatment with ranibizumab (RZB) for
centre involving DMO to evaluate the effect of treatment on
the VRIA and also to assess whether the presence of VRIA
had any effect on treatment outcomes.
Method
Information on consecutive patients commenced on RZB for
DMO between May 2013 and May 2014 at one ophthalmic
treatment centre (Sunderland Eye Infirmary, UK) were pro-
spectively entered onto an electronic data collection form.
Patients were eligible for treatment as per UK National
Institute for Health and Care Excellence criteria with centrally
involving DMO with a foveal retinal thickness of greater than
400 μm. Visual acuity (Va) was measured using an Early
Treatment Diabetic Retinopathy Study (ETDRS) chart at
2 m with best correction. Patients underwent spectral-
domain optical coherence tomography (30 by 30° horizontal
grid protocol with 60 μm line spacing) using a Spectralis
HRA + SDOCT (Heidelberg Engineering, Heidelberg,
Germany) at baseline and 12 months. Treatment was initiated
with four monthly RZB injections, with an additional two
following this if the oedema had not resolved (central retinal
thickness (CRT) <250 μm) or vision was less than 85 letters
followed by further injections as necessary using the Diabetic
Retinopathy Clinical Research Network protocol I andmonth-
ly follow-up [13]. At 12-month follow-up, SDOCT was ob-
tained using the Spectralis AutoRescan feature, matching the
position of the 12-month scan to the exact position of the
baseline scan.
At baseline the following information was recorded: age,
sex, type and duration of diabetes, HBA1c, retinopathy
grade (background, pre proliferative, active proliferative
or inactive treated proliferative retinopathy), and the occur-
rence of previous focal laser with the dates of the first mac-
ular laser as a surrogate for DMO duration. At each visit, Va,
CRT, and whether an injection or laser was given was
recoded, but for this study only the baseline and 12-month
data were used.
The baseline and 12-month SDOCTs were graded by an
observer masked to the outcome. The following parameters
were recorded: central retinal thickness (CRT: average retinal
thickness over the central 1 mm2), maximum retinal thickness
(MRT) anywhere in the central 1 mm2, the presence of
subretinal fluid, the presence of intraretinal cysts and the ver-
tical length of the longest cysts within the central 1 mm2 if
present, and the integrity of the ellipsoid zone graded as intact,
focally disrupted, or more severely disrupted based on a gap of
>1,000 μm in the central 1 mm2.
A variety of measures of the vitreoretinal interface were
recorded and graded by two observers, with the final grade
made by consensus in cases of disagreement. These included:
the presence of VMA (defined as perifoveal vitreoretinal sep-
aration within 2,500 μm of the foveal centre in any direction
with persistent vitreoretinal attachment at the fovea) and the
longest horizontal width of the attached zone through the fo-
veal centre if present, the presence of any foveal (within cen-
tral 1 mm2) and eccentric (outside central 1 mm2 but within
5 mm ETDRS circle) ERM (defined as a hyper-reflective in-
ner retinal band and graded as not present, present, or associ-
ated with retinal plication and/or peg-like attachments).
Baseline ERM was designated as clinically significant if the
following criteria were met:
1) ERM involving the foveal centre associatedwith a change
in foveal architecture and/or retinal surface wrinkling on
the fundal image.
2) Eccentric ERM if associated with retinal plication and/or
retinal surface wrinkling and in continuity with the central
zone of retinal thickening
The baseline and 12-month OCTs were compared to assess
whether there had been a change in the ERM (i.e., new ERM,
or the development of signs of retinal contracture in a linear
ERM) or VMA.
We defined stability of vision as being within 10 letters of
baseline Va, and improvement/reduction as being a change of
greater than 10 letters. Anatomical response was defined as a
reduction in CRT of 15% of baseline or more.
To be eligible for inclusion in the final analysis, patients
had to have had follow-up for 12 months after first injection
with baseline and 12-month SDOCT, and at least four consec-
utive RZB injections at the beginning. Patients with inactive
PDR previously treated with panretinal photocoagulation and
patients with previous focal laser injection for DMO were
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included, provided there had been no laser within 3 months of
the first RZB .
Patients were excluded if they had visually significant cat-
aract or cataract surgery during or within 3 months of the
study period, active PDR at baseline requiring panretinal pho-
tocoagulation, other intravitreal agents during the study peri-
od, and previous vitrectomy surgery. Under local protocols,
patients with significant tractional changes associated with
incomplete vitreoretinal separation (i.e., focal vitreomacular
attachment with alteration of foveal architecture) and DMO
were treated with vitrectomy and were not included.
Under UK guidelines the analysis was classified as a ser-
vice evaluation, and as such did not require ethical approval.
Statistical analysis
Descriptive and statistical analysis was performed using
Minitab 17 (Minitab Ltd, Coventry, UK). Patients’ demo-
graphic baseline characteristics are presented in terms of
mean, standard deviation (SD), and range or percentage as
appropriate. Similar information is presented when the data
was divided into groups. T-tests and one-way ANOVA were
used to compare continuous variables and chi-squared tests on
the categorical variables. A log transformation was used to
achieve normality if the Anderson–Darling statistics gave p-
values < 0.05 on the untransformed data. Mann–Whitney U-
tests were used on discrete data. When looking at the change
in variables following treatment, matched pairs t-tests were
used for continuous variables and McNemar’s test for binary
variables. For categorical variables with three categories, three
binary tables were produced and the minimum p-value for the
three McNemar’s test reported. General linear modelling with
a stepwise option was used to distinguish the most important
variables and present a predictive model for Va and CRT
change. Mixed modelling, fitting individual as a random ef-
fect, was used to check the significant results in cases where
there was a high intra-class correlation.
Results
During the study period, 132 eyes (96 patients) were treated
with RZB for DMO. Twenty-eight eyes (19 patients) were
excluded because of incomplete follow up (ten), cataract sur-
gery (two), active PDR (eight) and previous vitrectomy sur-
gery (three) as per our exclusion criteria, leaving 104 eyes (77
patients) for analysis.
Baseline features and overall response rate
The baseline features of the patients are shown in Table 1. The
mean patient age was 62 years (range 29–89), with 87% hav-
ing type 2 diabetes. Out of 77 included patients, the mean %
haemoglobin A1c was 8.2 and mean Va was 62 letters. The
mean CRT was 472, and 80% of the patients had pre-
proliferative or treated proliferative retinopathy. Sixty-six per-
cent of patients had previously been treated for maculopathy
with laser. Eleven of the cohorts were current smokers.
Eighteen patients (23%) had a history of ischaemic heart dis-
ease, and 13(17%) of cerebral vascular disease. None of the
patients in this cohort were receiving dialysis during the study
period or had had a renal transplant.
The overall 12-month outcomes for the cohort are given in
Table 2. The mean number of injections was seven (range 4–
11). Seventy-seven percent retained stable vision, whilst 16%
had an improvement in vision. The mean change in visual
Table 1 Demographics of entire
cohort Age: mean, SD (range) 62.1, 13.0 (29–89)
Sex n (%) (female/male) 29 F/48 M (38% / 62%)
Type of diabetes n (%) Type 1/Type 2 10/67 (13%/ 87%)
Diabetes duration: mean, SD (range) 14.3, 8.6 (1–45)
% Haemoglobin A1c: mean, SD, (range) 8.2, 1.7 (5–13.7)
Baseline Va: mean, SD (range) 61.6, 15.6 (5–85)
Baseline CRT: mean, SD (range) 471.8, 113.1 (270–856)
Baseline MRT: mean, SD (range) 544, 108 (400–968)
Retinopathy grade in treated eye n (%) for BDR, PPDR, PDR) 21, 43, 40 (20%, 41%, 39%)
Previous macular laser in treated eye n (%) 69 (66%)
Days to first laser for maculopathy: mean, SD (range) 660, 532 (91–1910)
Height of longest intraretinal cyst in microns: mean, SD (range) 295, 152, (0–947)
Presence of outer retinal changes n (%) for none, mild, severe (32, 30, 42) (31%, 29%, 40%)
Presence of SRF n (%) 40 (38%)
BDR background diabetic retinopathy, PPDR pre proliferative retinopathy, PDR inactive treated proliferative
retinopathy, CRT central retinal thickness, SD standard deviation, SRF subretinal fluid
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acuity was +3.4 letters and in CRT −127 μm. Overall, 73%
had an anatomical response to RZB.
Changes in SD OCT features of the cohort are shown in
Table 3. Both Va and retinal thickness decreased significantly.
Vitreomacular adhesion
At baseline, 39 eyes (37.5%) had associated VMA. At
12 months this had reduced to 30 (28.8%) (p = 0.04), with
12 eyes releasing VMA and three developing it. The mean
VMA width at baseline was 3,149 μm, which reduced to
2,732 μm post-treatment. There was a weak relationship be-
tween the VMAwidth at baseline and its subsequent release,
with those releasing having a mean width of 2,418 μm (range
242–2,479 μm) (p = 0.06).
The baseline features and outcome of the patients with and
without VMA at baseline are shown in Table 4. There were
more male patients with VMA than female. Patients with
VMA had both better presenting and final Va than those with-
out VMA. However, only the final Va remained significant
(p = 0.05) when mixed modelling was used. Otherwise there
were no significant differences.
Table 5 divides the presence of VMA into four groups:
VMA not present at any point in study, VMA present at base-
line and 12 months, VMA present at baseline and released at
12months, and finally those with VMA that developed during
the study. There was a significant difference in the improve-
ment in CRT, with the greatest improvement in those in whom
VMAwas present at baseline which then released during the
study (Fig. 1).
Epiretinal membrane
Forty-three percent of the cohort had some degree of foveal
involving ERM at baseline, and 63% some eccentric ERM. In
approximately one third of these patients, the ERM was asso-
ciated with retinal contracture with either retinal plication or
pegs visible. The total number of patients who were graded as
having significant ERM at baseline was 28. No patient devel-
oped clinically significant ERM at 12 months who didn’t have
it at baseline. There were 19 patients who developed a one-
step progression in ERM (i.e., who either developed new
ERM or who progressed from linear ERM to evidence of
contracture) from baseline to 12 months, and 21 patients
who had a reduction in ERM signs (no significant difference:
see supplementary tables S1 and S2). There was no associa-
tion between the presence of baseline ERM and its progres-
sion (p = 0.89)
Table 6 compares the features of those patients with and
without clinically significant ERM at baseline and 12 months.
There were significantly more female patients, more type 1
diabetics and more with previously treated proliferative dia-
betic retinopathy with significant ERM than without. Patients
with clinically significant ERM at baseline had a lower
starting visual acuity than those without, and significantly
worse final visual acuity. As before, the difference in baseline
visual acuity becomes non-significant when mixed modelling
is used, but the difference in final visual acuity is still highly
significant (p < 0.01). There was no difference in baseline
CRT between the groups, but the final CRT was significantly
worse in the ERM group (Fig. 2). The conclusions are the
same if mixed modelling is used. There was no significant
difference in the total number of injection received over the
treatment period (p = 0.71), the duration of maculopathy
(p = 0.75), or a history of previous laser (p = 0.79).
Table 2 Outcomes at 12 months for entire cohort
Number of injections
Mean, SD (range) 6.75, 1.51 (4–11)
Visual acuity stable n, % 80, 77%
Visual acuity worse n, % 7, 7%
Visual acuity improved n, % 17, 16%
Visual acuity change
Mean, SD (range) +3.4, 9.3 (−28–38)
CRT change
Mean, SD (range) −127, 116 (−422–203)
Anatomical response n, % 76, 73%
CRT central retinal thickness, SD standard deviation
Table 3 Changes in SD-OCT
features pre and post treatment in
treated eyes
Baseline Post P
Va mean, SD (range) 61.6, 15.6 (5–85) 65.0, 13.9 (26–87) <0.001a
CRT, mean, SD (range) 472, 113 (270–856) 345,100 (203–758) <0.001a
MRT mean, SD (range) 544, 108 (400–968) 410, 103 (274–813) <0.001a
CRT central retinal thickness,MRTmaximum retinal thickness, SD standard deviation, Va visual acuity, SD OCT
spectral-domain optical coherence tomography
amatched pairs t-test
Graefes Arch Clin Exp Ophthalmol
Multivariate analysis of factors affecting change
in outcomes with treatment
Multivariate analysis of the effect of all baseline features on
visual acuity and CRT change showed that the presence of an
increasing degree of ERM (clinically significant ERM > pres-
ence of foveal ERM with pegs or plication > linear foveal
ERM) and more severe retinopathy (proliferative > pre-
proliferative > background retinopathy) at baseline were pre-
dictive of less visual improvement (R2 = 15%, p < 0.01).
Shorter intraretinal cyst length, the presence of increasing
degrees of ERM, and the absence of VMA at baseline were
predictive of a worsened anatomical response (R2 = 42%,
p < 0.001).
No other baseline features including previous focal laser
and the duration of the DMO were predictive of outcome
Discussion
We describe a significant influence of vitreoretinal interface
abnormalities on anatomical and visual outcomes after intra-
vitreal RZB in patients with DMO. The effect was greater than
other differences previously described as being prognostically
important, including the presence of SRF and age [16, 17].
We found a high prevalence of ERM at baseline in patients
with DMO, in keeping with previous studies [1, 2], and found
that the presence of ERM was predictive of a more limited
response to RZB for both improvement in Va and reduction in
CRT at 12 months.
Only a few studies have investigated the effect of ERM on
response to anti-VEGF agents. Wu et al. studied 30 eyes treat-
ed with one anti-VEGF injection, and found an adverse effect
on Va and CRT response [18]. Yoon et al. studied 15 eyes after
Table 4 Comparison between
those with and without VMA at
baseline
VMA at baseline, n = 39 No VMA at baseline, n = 65 P
Age, years
Mean, SD (range) 60.7, 9.5 (29–71) 63.0, 14.8 (30–89) 0.47
Sex, n 7 female, 22 male 22 female, 26 male
(%) (female/male) (24%/76%) (46%/54%) 0.05
Retinopathy grade in treated
eye: n, (% for BDR, PPDR, PDR)
10, 18, 11 11, 25, 29
(26%, 46%, 28%) (16%, 38%, 45%) 0.23
Baseline visual acuity
Mean, SD (range) 65.4, 12.3 (34–85) 59.3, 17.0 (5–85) 0.05
Final visual acuity
Mean, SD (range) 69.2, 13.6 (31–87) 62.5, 13.6 (26–84) 0.02
Baseline CRT 0.47a
Mean, SD (range) 458, 86 (305–676) 480, 127 (270–856)
Final CRT
Mean, SD (range) 321, 81 (228–654) 359, 109 (203–758) 0.06a
CRT central retinal thickness, MRT maximum retinal thickness, SD standard deviation, Va Visual acuity, BDR
background diabetic retinopathy, PPDR pre proliferative retinopathy, PDR inactive treated proliferative
retinopathy
a log transformed
Table 5 Comparison between
the four VMA subgroups VMA group
No VMA
(n = 62)
VMA during
entire study
period
(n = 27)
VMA at baseline
that released
during study
(n = 12)
VMA that formed
during study (n = 3)
P
Change in Va, mean 3.3, 10.6 4.1. 7.0, 3.2, 8.4 −1.0, 1.0, 0.85
SD (range) (−28 to 38) (−15 to 17) (−17 to 16) (−2.0 to 1.0)
CRT change, mean −125, 122 −101, 103 −217, 80 −44, 60 0.01
SD (range) (−422 to 203) (−288 to 166) (−339 to −49) (−94 to 23)
Injections; mean 6.7, 1.4 6.9, 1.6 6.5, 1.6 7.3, 3.2 0.85
SD (range) (4–9) (4–11) (4–9) (5–11)
VMA vitreomacular adhesion, CRT central retinal thickness, SD standard deviation, Va visual acuity
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three injections, and found a negative effect on both outcomes
[19]. Importantly, however, both studies grouped all
vitreoretinal interface abnormalities together, including ERM
and VMA. Similarly Bressler et al. found an association of
‘surface wrinkling’ retinopathy on fundal photographs, with
poorer visual outcome after RZB [17]. This was undefined
and could have been related to vitreoretinal attachment.
They did not find that ‘OCT vitreoretinal abnormalities’ were
associated with Va outcome, but again this was a broad group
and difficult to interpret.
There are a number of reasons why eyes with pre-operative
ERMmay have a more limited response to anti-VEGF agents.
It may simply represent more severe baseline disease, with
chronic structural changes limiting potential visual improve-
ment. In support of this hypothesis, we found an association
between the presence of ERM and previously treated PDR and
poorer baseline Va. Against this, however, we found no asso-
ciation between our surrogate measure of chronicity of DMO
and the occurrence of clinically significant ERM, nor the fre-
quency of prior macular laser. Alternatively, the ERMmay be
limiting RZB penetration to the tissue and/or preventing the
restoration of normal anatomy and function mechanically.
We observed a relatively high prevalence of vitreomacular
adhesion at baseline similar to previous studies [20]. Recently,
Sadiq et al. showed a positive association of VMAwith visual
acuity, but not anatomical outcome in patients treated with
Fig. 1 Two patients with focal
(a) and broad (c) VMA at
baseline. First patient (a) has
spontaneous VMA release with
good anatomical response at
12 months (b) whilst second
patient (c) has persistent VMA
and retinal thickening (d)
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DMO in the READ-3 study participants [19]. At baseline and
at 12 months the Va in our VMA group was better than the
group without VMA concurring with Sadiq et al. However, on
multivariate analysis we found that only the anatomical re-
sponse to RZB was improved in the presence of VMA, with
the greatest response seen in those with VMA at baseline who
subsequently released the adhesion prior to the 12-month visit.
VMA release was relatively common, occurring in approx-
imately 25% of our cohort with VMA at baseline, similarly to
the findings of Sadiq et al. [19] This is in contrast to
Sivaprasad et al., who found an infrequent occurrence of
vitreomacular separation in patients with DMO after intravit-
real triamcinolone [21], and the 10% release rate in the control
arm of the MIVI Trust trial [22]. This perhaps relates to the
number of intravitreal injections given, a known precipitant of
vitreous separation. We only analysed SD OCT changes at
12 months, so do not know when VMA release occurred in
our patients. We did, however, find that a narrower attachment
of VMA was associated with a greater incidence of release
during treatment. Sivaprasad et al. and Sadiq et al. both de-
scribed an improvement in CRT after vitreoretinal release, as
we found. This is in contrast to the generally low incidence of
VMA release in wet AMD patients and the negative effect of
VMA at baseline on response to anti-VEGF agents, albeit
mainly on the need for and frequency of repeat injections
[23–25]. We did not find a difference in the number of RZB
injections on our PRN regime, but our study is limited in this
regard by its real-world nature. The difference in the impor-
tance of VMA at baseline between wet AMD and DMO is
difficult to explain, but our data support the findings of Sadiq
et al. that in DMO patients it should not be interpreted as an
indicator of a worsened prognosis.
There have been case reports of patients treated with DMO
using anti-VEGF agents developing a variety of new VRIAs
[26–28]. We, however, did not find any evidence for a sys-
tematic worsening in vitreoretinal traction in patients being
treated for DMO. Overall, 19 patients showed worsening of
ERM, but 21 patients showed signs of improvement in ERM
and no patient developed traction to an extent to warrant vit-
rectomy. This is contrary to the experience in patients with
active PDR being treated with anti-VEGF agents prior to vit-
rectomy, where increased retinal traction has frequently been
observed [29, 30]. It is thought that it is the alteration in the
balance between connective tissue growth factor (CTGF) and
VEGF that results in increasing fibrosis after anti-VEGF use,
termed the angiofibrotic switch [15]. Vitreous VEGF levels
are known to be higher in PDR [31, 32] than in patients with
DMO and NPDR, and CTGF levels are known to correlate
with the degree of intraocular fibrosis. Indeed, we found a
positive association between treated PDR and the occurrence
of clinically significant ERM in our cohort. However, we did
not find any association between the presence of ERM at
baseline and any worsening of ERM during treatment.
We excluded patients with active PDR requiring further
pan retinal photocoagulation, and it may be that these patients
with DMO would have a higher risk of VRIA exacerbation
with anti-VEGF agents.
Comparing our data to the RZB and deferred laser arm in the
landmark DRCR net trial [13], our overall visual results are
considerably worse (Va gain +3.4 in our study compared to
Table 6 Comparison between
those with and without clinically
significant ERM
Significant ERM at baseline,
n = 28
No significant ERM at baseline,
n = 76
p
Age; mean, SD, (range) 58.1, 17.1 (29–83) 63.7, 10.7 (30–89) 0.09
Sex n (%) (female/male) 13 F, 9 M (59%/31%) 16 F,39 M (29%/71%) 0.01
Type of diabetes
N (%) Type 1/Type 2 7/15 (32%/68%) 3/52 (5%/95%) 0.005
Retinopathy grade in treated
eye: n
(2, 8, 18) 19, 35, 22) 0.003
(% for BDR, PPDR, PDR) (7%, 29%, 64%) (25%, 46%, 29%)
Baseline visual acuity
Mean, SD (range) 57.4, 15.8 (17–83) 63.2, 15.4 (5–85) 0.10
Final visual acuity
Mean, SD, (range) 58.9, 17.2 (26–85) 67.3, 11.9 (38–87) 0.006
Baseline CRT
Mean, SD (range) 486, 149 (324–856) 467, 97 (270–785) 0.70a
Final CRT
Mean, SD (range) 407, 136 (219–758) 322, 72 (203–607) <0.001a
ERM epiretinal membrane, BDR background diabetic retinopathy, PPDR pre proliferative retinopathy, PDR
inactive treated proliferative retinopathy, CRT central retinal thickness, SD standard deviation, Va visual acuity
a log transformed
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+9 in the DRCR net), although interestingly the anatomical
responses were similar (127 μm versus 130 μm reduction) .
There are a number of possible reasons for this. The baseline
Vas was similar (62 versus 66 letters), but the baseline CRTwas
significantly higher in our study (471 versus 380 μm) with a
higher baseline HbA1c (8.2 versus 7.3), and a greater propor-
tion of eyes having previously had laser (66 versus 54% mac-
ular laser, and 39 versus 19% prior PRP). Similarly, the
chronicity of DMOwas probaly longer, all of which could have
affected the outcome [30]. The number of RZB injections given
was also lower (six versus nine) relating to real-world variabil-
ity in follow-up and attendance, as others have noted [33]. This
may also have affected the prevalence of ERM andVMA in our
cohort, although we found no association between a history of
previous laser, the duration of the DMO, nor other factors in-
cluding HbA1c with the occurrence of ERM or VMA.
Fig. 2 Two patients with foveal
involving ERM at baseline (a, c)
and at 12 months (b, d). Both
have signs of ERM contracture
with retinal plication which
persist at 12 months. d shows
some evidence of auto-release
temporally but both show
persistent thickening
Graefes Arch Clin Exp Ophthalmol
We acknowledge that the study has several weaknesses.
The cohort size was relatively small and non-controlled. It
was also real world, and therefore there were no protocol
refractions carried out, although visual acuities were mea-
sured in a standardised way using ETDRS letter charts. We
did not analyse the number of patient visits and the dura-
tion between visits; however, we did not find any differ-
ence in the number of injections between the subgroups
analysed. We only analysed outcomes at 12 months, and
it is possible our results could have been different after the
induction phase of four injections or using a different re-
gime. SD OCT is limited in its ability to classify cases of
complete vitreoretinal attachment or separation, and there-
fore in the absence of ultrasound findings we could only
grade VMA as present or not. Some of the cases without
VMA may have had complete vitreoretinal separation at
baseline. Our results therefore need to be interpreted with
this important caveat in mind. No correction has been
made for multiple testing, and so marginally significant
results need to be treated with caution. All eyes were in-
cluded in the analysis, but we found no significant associ-
ation between eyes within subjects for most of the end-
points studied. By treating patient as a random effect, the
within-patient correlation was calculated and tested using
ANOVA. For baseline Va, it was high and significant
(0.80). However, for post-treatment Va it drops to 0.38
and for change in Va it drops further to 0.26, and is not
significant in either case. For all measurements on CRT,
the within-patient correlation is non-significant and can be
ignored. Because of the high correlation for baseline Va
and, to a certain extent, post-treatment Va, mixed model-
ling was used to check the conclusions.
The study has several strengths including the prospective
data collection in the real-world and hence clinically appli-
cable setting. A standardised SDOCT imaging protocol was
followed and the AutoRescan function of the Spectralis
used, allowing each follow-up OCT scan to be registered
and locked to the baseline scan, thus enabling accurate
ERM and VMA progression to be analysed. All included
eyes had 12 months of follow-up with standardised injec-
tion protocol.
In conclusion, we found that VRIA are related to
outcome in patients treated with RZB and should be
considered in clinical decision making. ERM was asso-
ciated with a worsened visual and anatomic response
and VMA with an improved anatomical response, par-
ticularly when spontaneous VMA release occurred dur-
ing treatment. The presence and severity of ERM were
not affected by RZB treatment, in contrast to the wors-
ening of traction that can occur in eyes treated with
anti-VEGFs immediately prior to vitrectomy. Further
study of these changes in larger prospective trial
datasets is warranted.
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